Hua Jiang

Prof. Hua Jiang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2020 in APMIS
Verified
Journal Article
Open access
PDF file
YZYingqian Zhu
Yingqian Zhu
QLQingqing Li
Qingqing Li
HJHua Jiang
Hua Jiang
The increasing prevalence of cardiovascular diseases cannot adequately be explained by traditional risk factors. Recently, accumulating evidence has suggested that gut microbiota‐derived numerous metabolites are contributors to atherosclerotic events. Among them, the role of trimethylamine N‐oxide (TMAO) in promoting atherosclerosis has gained attention. TMAO is reported to exert the proatherogenic effects by impacting on the traditional risk factors of atherosclerosis and is associated with high risk of cardiovascular events. Besides that, TMAO is involved in the complex pathological processes of atherosclerotic lesion formation, such as endothelial dysfunction, platelet activation and thrombus generation. In light of these promising findings, TMAO may serve as a potential target for atherosclerosis prevention and treatment, which is conceptually novel, when compared with existing traditional treatments. It is likely that regulating TMAO production and associated gut microbiota may become a promising strategy for the anti‐atherosclerosis therapy.

1 November 2020 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Open access
XCXin Chen
Xin Chen
XZXi Zhou
Xi Zhou
HLHuan Li
Huan Li
JLJinlan Li
Jinlan Li
HJHua Jiang
Hua Jiang
The prevalence of chronic diseases in China has increased rapidly in recent decades. Although the management rate of chronic diseases has improved, there is still no unified and effective management measure for chronic diseases at present. This highlights the importance of effectively managing chronic diseases. With the development of e-health, the ways of getting medical consultation have changed. WeChat is an extremely popular social application in China. It is easy to operate and can offer multiple functions. Many researches have reported the effectiveness of WeChat in chronic diseases management. Based on the status of WeChat application in chronic diseases management and the characteristics of WeChat technology, we firstly focused on the WeChat application on the management of chronic diseases such as hypertension, diabetes, coronary heart disease and cancer. Then we discussed the value of WeChat in chronic diseases management and analyzed the potential reasons. Lastly, we discussed the limitations of present researches. WeChat can be an effective tool for the management of chronic diseases, but the promotion of this mode needs support and efforts from various aspects to eventually realize improving public health.

1 January 2021 in Theranostics
Verified
Journal Article
Open access
YZYingqian Zhu
Yingqian Zhu
JGJianli Ge
Jianli Ge
CHCe Huang
Ce Huang
HLHailiang Liu
Hailiang Liu
HJHua Jiang
Hua Jiang
Aging frailty is a complex geriatric syndrome that becomes more prevalent with advancing age. It constitutes a major health problem due to frequent adverse outcomes. Frailty is characterized by disruption of physiological homeostasis and progressive decline of health status. Multiple factors contribute to development of frailty with advancing age, including genome instability, DNA damage, epigenetic alternations, stem cell exhaustion, among others. These interrelated factors comprehensively result in loss of tissue homeostasis and diminished reserve capacity in frailty. Therefore, the aged organism gradually represents symptoms of frailty with decline in physiological functions of organs. Notably, the brain, cardiovascular system, skeletal muscle, and endocrine system are intrinsically interrelated to frailty. The patients with frailty may display the diminished reserves capacity of organ systems. Due to the complex pathophysiology, no specific treatments have been approved for prevention of this syndrome. At such, effective strategies for intervening in pathogenic process to improve health status of frail patients are highly needed. Recent progress in cell-based therapy has greatly contributed to the amelioration of degenerative diseases related to age. Mesenchymal stem cells (MSCs) can exert regenerative effects and possess anti-inflammatory properties. Transplantation of MSCs represents as a promising therapeutic strategy to address the pathophysiologic problems of frail syndrome. Currently, MSC therapy have undergone the phase I and II trials in human subjects that have endorsed the safety and efficacy of MSCs for aging frailty. However, despite these positive results, caution is still needed with regard to potential to form tumors, and further large-scale studies are warranted to confirm the therapeutic efficacy of MSC therapy.

17 May 2024 in Journal of Global Health
Verified
Journal Article
Open access
SHSupei Hu
Supei Hu
XWXianjiang Wu
Xianjiang Wu
HJHua Jiang
Hua Jiang
Thyroid cancer has become a significant global health concern [1], with its continually increasing incidence over the past few decades making it one of the most common endocrine system malignancies [2,3]. This has had far-reaching consequences for the overall health and quality of life of patients [4,5]. The disease is characterised by disparities between various […]

14 August 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
QHQian Huang
Qian Huang
YLYang Li
Yang Li
MYMinggang Yu
Minggang Yu
ZLZhizi Lv
Zhizi Lv
FLFengyi Lu
Fengyi Lu
HJHua Jiang
Hua Jiang
Background: Type 2 diabetes mellitus (T2DM) presents a substantial strain on global healthcare systems. This study seeks to offer robust scientific evidence for the effective prevention and management of T2DM globally through a comprehensive analysis of the disease’s burden, trends, and risk factors from 1990 to 2021, as well as future trajectories from 2022 to 2050.Methods: Data for this study were sourced from the 2021 Global Burden of Disease (GBD) study. T2DM burden was assessed through incidence, prevalence, mortality, and disability-adjusted life years (DALYs), stratified by age, sex, sociodemographic index (SDI), 21 GBD regions, and 204 countries/territories. Trends from 1990 to 2021 were quantified by estimating annual percentage changes. Decomposition analysis identified the primary population-level drivers of T2DM burden changes. The population attributable fraction assessed the contribution of risk factors to the T2DM burden over the past 30 years, while the Bayesian age–period–cohort model was employed to predict the future burden driven by risk factors.Results: In 2021, T2DM affected 506.0 million individuals, with 23.9 million new cases, 1.6 million deaths, and 75.3 million DALYs. Between 1990 and 2021, both absolute and relative burdens of T2DM increased, particularly among males, older adults, and individuals under 40. Regions with higher SDI generally exhibited higher age-standardized incidence and prevalence rates, while those with lower SDI had elevated age-standardized mortality and DALY rates. Oceania stood out as an exception, with the highest relative burdens across all four indicators, most notably in the Marshall Islands and Fiji. The increases in incidence, DALYs, and prevalence were predominantly driven by population growth and epidemiological shifts, with aging contributing significantly to the rise in mortality. Elevated fasting plasma glucose, body mass index (BMI), and particulate pollution were major contributors to higher T2DM-related mortality and DALY rates. By 2050, high BMI, alcohol consumption, and sugary beverages are anticipated to increasingly influence the T2DM burden.Conclusion: Focused, preventive interventions targeting key risk factors in high-burden groups can effectively reduce the global T2DM burden.

25 March 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
YGYanmin Gao
Yanmin Gao
YMYanli Ma
Yanli Ma
DXDi Xie
Di Xie
HJHua Jiang
Hua Jiang